Objective: To evaluate effectiveness of directly observed treatment short course (DOTS) by monthly sputum conversion rates at first, second, and third month in newly diagnosed patients of pulmonary tuberculosis (TB) (category-1), and to study patterns of lesions on chest radiographs and their correlation to smear sputum positivity, also to record reaction to Mantoux tuberculin skin test (TST) in active TB patients.
Methods: This prospective cohort study was conducted among 100 newly diagnosed patients of open pulmonary tuberculosis CAT-1, admitted and treated under DOTS, at the Tuberculosis Center, Dammam Medical Complex, Dammam, Kingdom of Saudi Arabia between July to December 2010. Chest radiographs were studied for the patterns of lesions and their correlation to the grades of sputum positivity. Three fasting state sputum specimens were tested on 3 consecutive days by direct smear microscopy at first, second, and third month. As per DOTS, intensive phase treatment was extended for another 4 weeks in those still positive at the end of 2 months. Mantoux TST was performed on all patients with tuberculin purified protein derivative-RT-23 2TU.
Results: The overall sputum conversion rate observed at the first month was 56%, 76% on the second month, and 94% on the third month. Reaction to TST of more than 10 mm was recorded in most of the studied patients (97%).
Conclusion: The DOTS is an appropriate strategy for early and progressive conversion of smear positive patients to break the chain of infection, which is epidemiologically important for the control, elimination, and eradication of TB.
Download full-text PDF |
Source |
---|
Clin Infect Dis
January 2025
EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
Background: Higher than standard doses of rifampicin could improve the treatment outcome of drug-susceptible tuberculosis without compromising the safety of patients.
Methods: We performed a systematic review of prospective clinical studies including adults with pulmonary and extrapulmonary TB receiving rifampicin doses above 10mg/kg/day. We extracted the data on overall adverse events (AE), hepatic AE, sputum culture conversion (SCC) at week 8, recurrence, mortality, and pharmacokinetics.
Antibiotics (Basel)
December 2024
Pharmacogenetic and Precision Medicine Laboratory, Pharmaceutical Education and Research Centre, Riga Stradins University, Konsula Street 21, LV1007 Riga, Latvia.
Serum C-reactive protein (CRP) levels vary depending on radiological and bacteriological findings at the time of tuberculosis (TB) diagnosis. However, the utility of this biomarker in monitoring response to anti-TB treatment and identifying patients at risk of treatment failure is not well established. This study evaluated the impact of patients' baseline characteristics and anti-TB drug plasma exposure on the early reduction in serum CRP levels and its relationship with treatment response.
View Article and Find Full Text PDFInt J Tuberc Lung Dis
January 2025
Department of Pharmacology and Therapeutics, Makerere College of Health Sciences, Kampala, Uganda.
Cureus
November 2024
Pulmonology, Unidade Local de Saúde Amadora/Sintra, Amadora, PRT.
Introduction The prevalence of nontuberculous mycobacteria (NTM) is higher in patients with structural lung disease and in immunocompromised patients. Lung involvement is the most common. The complex corresponds to the most identified agent.
View Article and Find Full Text PDFJ Infect
December 2024
German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Division of Clinical Infectious Diseases, Research Center Borstel, Parkallee 1-40, 23845 Borstel, Germany.
Objectives: Early detection of treatment failure is essential to improve the management of drug-resistant tuberculosis (DR-TB). We evaluated the molecular bacterial load assay (MBLA) in comparison to standard diagnostic tests for monitoring therapy of patients affected by drug-resistant TB.
Methods: The performance of MBLA in tracking treatment response in a prospective cohort of patients with pulmonary MDR/RR- and pre-XDR/XDR-TB was compared with mycobacterial culture, mycobacterial DNA detection using GeneXpert (Xpert) and microscopy detection of sputum acid-fast-bacilli.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!